A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy
Latest Information Update: 06 Mar 2025
Price :
$35 *
At a glance
- Drugs Upadacitinib
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms U-ASTOUND
- Sponsors AbbVie
- 06 Dec 2024 Planned End Date changed from 31 Oct 2033 to 1 Oct 2033.
- 06 Dec 2024 Planned primary completion date changed from 12 Aug 2028 to 1 Aug 2028.
- 09 Oct 2023 Status changed from not yet recruiting to recruiting.